We recently traveled to New York City, New York for a State of the Science Summit™ on Breast Cancer, where we spoke with Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, and Alan B. Astrow, MD, a professor of medicine at Weill Cornell Medicine, and chief of hematology and medical oncology at New York Methodist Hospital. In our discussion, Drs Newman and Astrow discussed the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.